Literature DB >> 9194486

Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.

Y Yaginuma1, H Hayashi, K Kawai, T Kurakane, Y Saitoh, S Kitamura, K Sengoku, M Ishikawa.   

Abstract

In the present study, we analyzed human ovarian carcinoma cell lines for abnormalities in the tumor suppressor gene Rb (retinoblastoma) and in cyclin-dependent kinase 4 (CDK4) inhibitor genes (p16INK4 and p15INK4B) using molecular biology techniques. For the Rb gene, in all six cell lines (PA-1, Caov-3 and -4, OVCAR-3, SK-OV-3, and Kuramochi), Rb gene abnormality was not detected using Southern blotting. In the Caov-3 cell line transcripts were not detectable by either Northern blot or polymerase chain reaction. Sequence analysis of the entire coding region of the Rb gene revealed point mutations (AAC to GAC) resulting in codon 123 (Asn to Asp) changes in the Caov-4 cell line. In the PA-1 cell line both wild-type Rb and mutant-type Rb (codon 798: CGG to TGG) were expressed, and in the OVCAR-3 cell line both wild-type Rb and mutant-type Rb (codon 704: ATG to GTG) were expressed. In four of six human ovarian carcinoma cell lines Rb gene abnormality was detected. For the p16INK4 and p15INK4B genes, only the SK-OV-3 cell line had abnormalities. There was a gene rearrangement or minor deletion of the p16INK4 gene in the SK-OV-3 cell line, while the p15INK4B gene was deleted in this cell line. In the SK-OV-3 cell line no mRNAs of p16INK4 and p15INK4B were expressed. At the point of Rb gene inactivation, we can explain five cell lines of six: four cell lines had abnormalities in the Rb gene itself, which is another mechanism by which the Rb gene is inactivated, while one cell line (SK-OV-3) had abnormalities in CDK4 inhibitor genes, another of the inactivation mechanisms of the Rb gene. These data suggest that abnormalities of Rb and CDK4 inhibitor genes (p16INK4, p15INK4B) may be involved in human ovarian carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194486     DOI: 10.1006/excr.1997.3560

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

Review 2.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

Review 3.  Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.

Authors:  Uma M Sachdeva; Joan M O'Brien
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

4.  Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Authors:  Lidia Hernandez; Marianne K Kim; L Tiffany Lyle; Kristen P Bunch; Carrie D House; Franklin Ning; Anne M Noonan; Christina M Annunziata
Journal:  Gynecol Oncol       Date:  2016-05-28       Impact factor: 5.482

5.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  A cancer derived mutation in the retinoblastoma gene with a distinct defect for LXCXE dependent interactions.

Authors:  Shauna A Henley; Sarah M Francis; Jordan Demone; Peter Ainsworth; Frederick A Dick
Journal:  Cancer Cell Int       Date:  2010-03-18       Impact factor: 5.722

7.  p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.

Authors:  Magdalena B Flak; Claire M Connell; Claude Chelala; Kyra Archibald; Michael A Salako; Katrina J Pirlo; Michelle Lockley; Sally P Wheatley; Frances R Balkwill; Iain A McNeish
Journal:  Mol Cancer       Date:  2010-07-03       Impact factor: 27.401

8.  Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.

Authors:  S K Baird; J L Aerts; A Eddaoudi; M Lockley; N R Lemoine; I A McNeish
Journal:  Oncogene       Date:  2007-12-10       Impact factor: 9.867

9.  p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas.

Authors:  Andrzej Semczuk; Carsten Boltze; Barbara Marzec; Anna Szczygielska; Albert Roessner; Regine Schneider-Stock
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-14       Impact factor: 4.553

10.  Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.

Authors:  Claire M Connell; Atsushi Shibata; Laura A Tookman; Kyra M Archibald; Magdalena B Flak; Katrina J Pirlo; Michelle Lockley; Sally P Wheatley; Iain A McNeish
Journal:  J Clin Invest       Date:  2011-03-07       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.